Literature DB >> 31382785

Immune therapy, a double-edged sword for oncolytic viruses.

Ryan M McCormack1, Balveen Kaur1.   

Abstract

Entities:  

Keywords:  Oncolytic viruses; immunity; tumor associated macrophages; tumor microenvironment

Year:  2019        PMID： 31382785      PMCID： PMC6863343          DOI： 10.1080/14712598.2019.1650911

Source DB:  PubMed          Journal:  Expert Opin Biol Ther        ISSN： 1471-2598            Impact factor:   4.388


× No keyword cloud information.
  16 in total

Review 1.  Macrophage diversity enhances tumor progression and metastasis.

Authors:  Bin-Zhi Qian; Jeffrey W Pollard
Journal:  Cell       Date:  2010-04-02       Impact factor: 41.582

2.  The Impact of Macrophage- and Microglia-Secreted TNFα on Oncolytic HSV-1 Therapy in the Glioblastoma Tumor Microenvironment.

Authors:  W Hans Meisen; Eric S Wohleb; Alena Cristina Jaime-Ramirez; Chelsea Bolyard; Ji Young Yoo; Luke Russell; Jayson Hardcastle; Samuel Dubin; Kamaldeen Muili; Jianhua Yu; Michael Caligiuri; Jonathan Godbout; Balveen Kaur
Journal:  Clin Cancer Res       Date:  2015-03-31       Impact factor: 12.531

3.  Shaping the Tumor Stroma and Sparking Immune Activation by CD40 and 4-1BB Signaling Induced by an Armed Oncolytic Virus.

Authors:  Emma Eriksson; Ioanna Milenova; Jessica Wenthe; Magnus Ståhle; Justyna Leja-Jarblad; Gustav Ullenhag; Anna Dimberg; Raphael Moreno; Ramon Alemany; Angelica Loskog
Journal:  Clin Cancer Res       Date:  2017-05-23       Impact factor: 12.531

4.  Copper chelation enhances antitumor efficacy and systemic delivery of oncolytic HSV.

Authors:  Ji Young Yoo; Jason Pradarelli; Amy Haseley; Jeffrey Wojton; Azeem Kaka; Anna Bratasz; Christopher A Alvarez-Breckenridge; Jun-Ge Yu; Kimerly Powell; Andrew P Mazar; Theodoros N Teknos; E Antonio Chiocca; Joseph C Glorioso; Matthew Old; Balveen Kaur
Journal:  Clin Cancer Res       Date:  2012-07-02       Impact factor: 12.531

5.  Oncolytic Virotherapy Blockade by Microglia and Macrophages Requires STAT1/3.

Authors:  Zahid M Delwar; Yvonne Kuo; Yan H Wen; Paul S Rennie; William Jia
Journal:  Cancer Res       Date:  2017-11-08       Impact factor: 12.701

Review 6.  The Yin-Yang of tumor-associated macrophages in neoplastic progression and immune surveillance.

Authors:  Paola Allavena; Antonio Sica; Cecilia Garlanda; Alberto Mantovani
Journal:  Immunol Rev       Date:  2008-04       Impact factor: 12.988

7.  Role of cysteine-rich 61 protein (CCN1) in macrophage-mediated oncolytic herpes simplex virus clearance.

Authors:  Amy Haseley Thorne; Walter H Meisen; Luke Russell; Ji Young Yoo; Chelsea M Bolyard; Justin D Lathia; Jeremy Rich; Vinay K Puduvalli; Hsiaoyin Mao; Jianhua Yu; Michael A Caligiuri; Susheela Tridandapani; Balveen Kaur
Journal:  Mol Ther       Date:  2014-06-04       Impact factor: 11.454

8.  Randomized, Open-Label Phase II Study Evaluating the Efficacy and Safety of Talimogene Laherparepvec in Combination With Ipilimumab Versus Ipilimumab Alone in Patients With Advanced, Unresectable Melanoma.

Authors:  Jason Chesney; Igor Puzanov; Frances Collichio; Parminder Singh; Mohammed M Milhem; John Glaspy; Omid Hamid; Merrick Ross; Philip Friedlander; Claus Garbe; Theodore F Logan; Axel Hauschild; Celeste Lebbé; Lisa Chen; Jenny J Kim; Jennifer Gansert; Robert H I Andtbacka; Howard L Kaufman
Journal:  J Clin Oncol       Date:  2017-10-05       Impact factor: 44.544

9.  Cardiotoxicity associated with CTLA4 and PD1 blocking immunotherapy.

Authors:  Lucie Heinzerling; Patrick A Ott; F Stephen Hodi; Aliya N Husain; Azadeh Tajmir-Riahi; Hussein Tawbi; Matthias Pauschinger; Thomas F Gajewski; Evan J Lipson; Jason J Luke
Journal:  J Immunother Cancer       Date:  2016-08-16       Impact factor: 13.751

Review 10.  Immune related adverse events associated with anti-CTLA-4 antibodies: systematic review and meta-analysis.

Authors:  Anne Bertrand; Marie Kostine; Thomas Barnetche; Marie-Elise Truchetet; Thierry Schaeverbeke
Journal:  BMC Med       Date:  2015-09-04       Impact factor: 8.775
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.